The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of COYA 301 in 8 patients with Alzheimer’s disease (AD). The ...

Researchers at Tsukuba University have discovered that the increase in regulatory T (Treg) cells, which typically suppress immune responses, does not adequately control elderly-onset rheumatoid ...

A special group of immune cells known as regulatory T cells, or Tregs for short, became an overnight sensation when a trio of U.S. and Japanese scientists won the Nobel Prize in physiology or medicine ...

Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...

Regulatory T cells (Tregs) could be developed into ‘living drugs’ capable of restoring immune tolerance and treating a wide ...

3D rendering of the tumor microenvironment. The recipe for a general and long-lasting cancer treatment could involve regulatory T cells, a type of white blood cell. This is the first installment in a ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...

New research findings show in detail how self-reactive T cells -- white blood cells dubbed Teffs that mistakenly attack healthy instead of infected cells, thereby causing an autoimmune or an ...

"Peacemaker" immune cells could help treat diseases ranging from type 1 diabetes to neurodegeneration by restoring immune ...